CBAY — CymaBay Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.73bn
- $3.44bn
- $31.07m
CymaBay Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Cymabay Therapeutics Announces Publication Of Results From The Enhance, Phase 3 Study Of Seladelpar In Patients With Primary Biliary Cholangitis (PBC)
William Blair initiates CymaBay with 'outperform' on liver disease therapy potential
U.S. RESEARCH ROUNDUP-Douglas Emmett, Meta Platforms, ServiceNow
Brief: Cymabay Therapeutics Inc Files For Mixed Shelf, Size Not Disclosed - SEC Filing
U.S. RESEARCH ROUNDUP-Amazon.com, Dell, Unum Group, Penumbra
U.S. RESEARCH ROUNDUP-Amazon.Com, Unum Group, Penumbra
Brief: Cymabay Reports Fourth Quarter Loss Per Share $0.30
Cymabay Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Cymabay Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: CymaBay Therapeutics Says As Of March 13, Co Had Depository Accounts At SVB In Which It Held About $6.3 Million
Brief: Perceptive Advisors Reports 5.6% Passive Stake In Cymabay Therapeutics Inc - SEC Filing
U.S. RESEARCH ROUNDUP-Esperion Therapeutics, Office Properties Income Trust, Radius Global Infrastructure
U.S. RESEARCH ROUNDUP-G1 Therapeutics, Kemper, Stellar Bancorp
U.S. STOCKS ON THE MOVE-Baudax Bio , GATX Corp, Verb Technology, Decibel Therapeutics
U.S. STOCKS ON THE MOVE-PACCAR, Cullinan Oncology, 3M, Peloton
U.S. STOCKS ON THE MOVE-HighPeak Energy , CymaBay Therapeutics, Polypid
CymaBay Therapeutics jumps on pricing upsized stock offering at premium
Brief: Cymabay Announces Pricing Of Public Offering Of Shares, Pre-Funded Warrants